Product IntroductionBioactivity英文名:
SB-200646A描述: SB-200646A 是一个对 5-HT2B/2C 的选择性超过 5-HT2A 的拮抗剂,5-HT2B,5-HT2C 和 5-HT2A 的 pKi 值分别为 7.5、6.9 和 5.2。SB-200646A 具有口服活性,在体内具有电生理和抗焦虑特性。
体外活性: SB200646A (4 μM) abolishes the ethanol-induced increase in miniature inhibitory postsynaptic current (mIPSC) frequency and had no effect on basal mIPSC frequency.
体内活性: SB-200646A (20 mg/kg; intravenous injection; daily; for 21 days; male albino Sprague-Dawley rats) treatment significantly decreases the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons. The i.v. administration of 4-16 mg/kg of SB-200646A significantly increases the firing rate and % events as bursts in spontaneously active VTA dopaminergic neurons and significantly increases the % events as burst in substantia nigra pars compacta (SNC) dopaminergic neurons[1].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 225 mg/mL (743.2 mM)
关键字:
SB 200646A |
SB200646A |
SB-200646A相关产品:
Promethazine |
CLOZAPINE N-OXIDE |
Xaliproden hydrochloride |
SB 258585 |
Onitisin |
Org 13011 |
H-9 dihydrochloride |
SAX-187 |
Aplindore Fumarate |
Sevoflurane